Review
Nature Reviews Microbiology 6, 529-540 (July 2008) | doi:10.1038/nrmicro1927
Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded
Roberto Cattaneo1, Tanner Miest1, Elena V. Shashkova2 & Michael A. Barry2,3 About the authors
Abstract
Virotherapy is currently undergoing a renaissance, based on our improved understanding of virus biology and genetics and our better knowledge of many different types of cancer. Viruses can be reprogrammed into oncolytic vectors by combining three types of modification: targeting, arming and shielding. Targeting introduces multiple layers of cancer specificity and improves safety and efficacy; arming occurs through the expression of prodrug convertases and cytokines; and coating with polymers and the sequential usage of different envelopes or capsids provides shielding from the host immune response. Virus-based therapeutics are beginning to find their place in cancer clinical practice, in combination with chemotherapy and radiation.
- View At a Glance
Author affiliations
- Department of Molecular Medicine, Rochester, 55905 Minnesota, USA.
- Department of Internal Medicine, Rochester, 55905 Minnesota, USA.
- Department of Immunology, Division of Infectious Diseases, Translational Immunovirology and Biodefense Program, Mayo Clinic, Rochester, 55905 Minnesota, USA.
Correspondence to: Roberto Cattaneo1 Email: Cattaneo.Roberto@mayo.edu;
Correspondence to: Michael A. Barry2,3 Email: Barry.Michael@mayo.edu
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
An Immunocompetent Murine Model for Oncolysis with an Armed and Targeted Measles VirusMolecular Therapy Original Article
Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodiesGene Therapy Original Article
Targeted Cell Entry of Lentiviral VectorsMolecular Therapy Original Article
See all 48 matches for Research
